Wells Fargo & Company Cuts Cellectis (NASDAQ:CLLS) Price Target to $3.00

Cellectis (NASDAQ:CLLS) had its price objective cut by Wells Fargo & Company from $4.00 to $3.00 in a report issued on Tuesday morning, MarketBeat reports. They currently have an equal weight rating on the biotechnology company’s stock.

CLLS has been the subject of a number of other reports. Barclays assumed coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price objective for the company. Citizens Jmp reiterated a “market perform” rating on shares of Cellectis in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Cellectis has a consensus rating of “Hold” and a consensus target price of $5.46.

Cellectis Trading Up 6.2%

NASDAQ:CLLS opened at $1.46 on Tuesday. Cellectis has a 12-month low of $1.25 and a 12-month high of $5.48. The firm has a market capitalization of $146.50 million, a P/E ratio of -2.25 and a beta of 2.92. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. The business has a 50 day simple moving average of $2.90 and a 200 day simple moving average of $3.28.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC bought a new position in shares of Cellectis S.A. (NASDAQ:CLLS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is currently owned by institutional investors.

Cellectis News Summary

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to prioritize two preclinical in vivo gene-editing programs, a strategy that could provide a more focused path toward genetic medicines and potentially reduce internal development costs. The company is also seeking partners to continue development of the discontinued CAR-T programs. Cellectis Exits Two CAR-T Programs
• Neutral Sentiment: An analysis characterized the pivot as an “all or nothing” transition that warrants monitoring. The opportunity depends on whether Cellectis can demonstrate meaningful progress with its early-stage in vivo gene-editing platform. Cellectis In Vivo Gene-Editing Analysis
• Neutral Sentiment: Citizens JMP reiterated a Market Perform rating, indicating limited conviction that the strategic transformation will drive near-term outperformance. Citizens JMP Market Perform Rating
• Negative Sentiment: Analysts lowered their expectations for Cellectis. Wells Fargo reduced its price target to $3.00, while Robert W. Baird also lowered its expectations following the pipeline pivot. These actions reflect weaker near-term visibility after the company abandoned internal development of two CAR-T candidates. Wells Fargo Lowers Cellectis Price Target Baird Lowers Cellectis Expectations
• Negative Sentiment: Several law firms announced investigations into whether Cellectis complied with federal securities laws in connection with disclosures surrounding the strategic transformation. These announcements add potential legal and reputational overhang, although they do not establish wrongdoing. Holzer and Holzer Cellectis Investigation Frank R. Cruz Cellectis Investigation

Cellectis Company Profile

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.